The Food and Drug Administration (FDA) has approved extended dosing intervals for Eylea HD ® (aflibercept) for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME ...

Improvement in QoL, other PROs seen for those who switched to tirzepatide after not achieving glycemic control on stable dose of dulaglutide.

HealthDay News — Glucagon-like peptide-1 (GLP-1) receptor agonist (RA) use is associated with delayed wound healing in patients undergoing abdominal panniculectomy, according to a study published in ...

Incidence of primary end point lower for patients with target LDL level less than 55mg/dL vs less than 70mg/dL.

Expanding eligibility for full LIS to include Medicare beneficiaries with incomes between 135 and 150 percent of FPL reduces cost-related medication nonadherence ...

Confirmatory ZUMA-2 trial data led to full FDA approval of brexucabtagene autoleucel for patients with relapsed or refractory mantle cell lymphoma.

Participants did demonstrate greater proptosis improvement from baseline following the initial high dose period vs after the ...

HealthDay News — International guidelines are presented for the treatment of adults and children with sepsis and septic shock in 2 special articles from the Surviving Sepsis Campaign, published online ...

The Food and Drug Administration (FDA) has granted Fast Track designation to CDI-988 for treatment and prophylaxis of norovirus infection.

Discontinuing β-blockers after one year or longer is noninferior for all-cause death, recurrent MI, or hospitalization for heart failure.

Interim data also suggested a strong trend toward improved PFS and OS when evaluating the STRIDE regimen in combination with TACE vs TACE alone.

The table below is a review of notable updates that occurred in March 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.